Massive study investigates cancer risk of popular diabetes drug
NCT ID NCT04572165
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzed health records from nearly 195,000 people in Denmark, Sweden, and Norway to see if semaglutide (the drug in Ozempic and Rybelsus) is linked to a higher risk of pancreatic cancer. Researchers compared new users of semaglutide to new users of other diabetes medications. The goal was to gather safety information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Southern Denmark
Odense, 5000, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a heart drug tame blood sugar and weight in diabetes?
- Can a puff of insulin replace a needle for diabetes?
- Could a quick insulin shot stop Steroid-Induced blood sugar spikes?
- Can a puff of insulin replace a daily shot for diabetes?
- Could a Dairy-Rich diet tame type 2 diabetes?
- Can a traditional herbal remedy tame type 2 diabetes?